GE91 Stock Chart & Stats
€29.20
-€0.40(-1.59%)
At close: 4:00 PM EDT
€29.20
-€0.40(-1.59%)
Day’s Range― - ―
52-Week Range€20.20 - €30.40
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
€18.07B
Enterprise Value€20.72K
Total Cash (Recent Filing)€1.50B
Total Debt (Recent Filing)€5.27B
Price to Earnings (P/E)27.3
Beta0.58
Next Earnings
Nov 05, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.28
Shares Outstanding624,058,530
10 Day Avg. Volume0
30 Day Avg. Volume1
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)3.28
Price to Sales (P/S)5.14
P/FCF Ratio16.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€82.59Price Target Upside182.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)1.04
Revenue Forecast (FY)€3.91B
Bulls Say, Bears Say
Bulls Say
Commercial GrowthStrong H1 revenue growth and a raised full-year outlook indicate expanding commercial demand across Genmab’s portfolio. The upgrade was driven by royalty streams and EPKINLY, suggesting growth is supported by multiple established revenue sources rather than a single temporary contribution.
Diversified Product PortfolioGrowth across DARZALEX, EPKINLY, and the broader portfolio provides meaningful diversification within Genmab’s commercial base. Broad-based product expansion can reduce reliance on one therapy, support more resilient royalty and product revenue, and strengthen the platform’s ability to compound.
Clinical And Regulatory ProgressThe positive Phase III result strengthens epcoritamab’s clinical profile and supports potential expansion across B-cell malignancies. Combined with European approval in second-line follicular lymphoma and additional Phase III launches, this advances Genmab’s pipeline toward durable commercial opportunities.
Bears Say
Margin CompressionThe sharp decline in operating and net margins indicates that recent revenue growth is not translating into prior levels of profitability. Higher R&D, commercialization, and integration spending may continue to pressure earnings until pipeline investment and launches generate sufficient operating leverage.
Higher LeverageDebt approaching equity represents a material change in Genmab’s balance-sheet profile and reduces financial flexibility. Greater leverage can constrain capital allocation while profitability is under pressure, making it more important for future operating performance and cash generation to remain strong.
Competitive PressureCrowded oncology markets could make it harder for Genmab’s petosemtamab and Rina-S programs to achieve durable differentiation and adoption. Competitor advances may increase development requirements, intensify commercial execution demands, and limit the long-term contribution of these pipeline assets.
Genmab News
GE91 FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was €20.20 and its highest was €30.40 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is €18.07B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Nov 05, 2026 which is in 43 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Aug 06, 2026. The company reported €0.429 earnings per share for the quarter, beating the consensus estimate of €0.311 by €0.118.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 0.33.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 624,058,530 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of €0.429 in its last earnings report, beating expectations of €0.311. Following the earnings report the stock price went up 0.8%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in DE:GE91
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genmab Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€82.59 (182.83% Upside)
€82.59 (182.83% Upside)
Blogger Sentiment
Bullish
DE:GE91 Sentiment 86%
Sector Average 63%
Sector Average 63%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
93.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Genmab A/S
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.
GE91 Company Deck
GE91 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Genmab presented a strongly positive commercial and financial performance in H1 2026 — double-digit revenue and operating profit growth, upgraded full-year guidance, robust Epkinly momentum, meaningful product sales (DARZALEX, EPKINLY, TIVDAK), and multiple late-stage clinical advances including a positive Phase III PFS readout and new Phase III initiations. The company also acknowledged execution uncertainties: several data readouts remain event-driven or immature (OS not yet mature), competition across key indications is intensifying, some trial timing/readout clarifications raised investor questions, and integration/IP/tax factors introduce near-term modeling uncertainty. On balance the operational and financial momentum and near-term catalyst calendar outweigh the challenges, supporting a constructive outlook.View all DE:GE91 earnings summariesGE91 Stock 12 Month Forecast
Average Price Target
€82.59
▲(182.83% Upside)